Yang Gao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yang Gao has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Hao Wang
School of Physics, Beihang University, Beijing, China
2 shared publications - Junjie Wang
Department of Radiation Oncology, Peking University Third Hospital, China
2 shared publications - Chen Liu
Department of Interventional Therapy, Beijing Cancer Hospital, Beijing, China
1 shared publication - Dianrong Xiu
Department of Surgery, Peking University 3rd Hospital, Beijing 100083, P. R. China
1 shared publication - Jinna Li
Department of Radiation Oncology, Peking University 3rd Hospital, Huan-yuan North Road 49th, Beijing 100083, P. R. China
1 shared publication - Kaixian Zhang
Department of Oncology, Tengzhou Central People's Hospital, Affiliated to Jining Medical College, Tengzhou, China
1 shared publication
Latest Publications
- Open Access
- 23 December 2014
- Published by Springer Nature in Radiation Oncology
- Vol. 9 (1) , 301
CT-guidance interstitial 125Iodine seed brachytherapy as a salvage therapy for recurrent spinal primary tumors
Management of spinal neoplasms has relied on open surgery and external beam radiotherapy (EBRT). Although primary spinal tumors are rare, their treatment remains a pervasive problem. This analysis sought to evaluate the safety and efficacy of CT-guided 125I seed brachytherapy for recurrent paraspinous and vertebral primary tumors. From November 2002 to June 2014, 17 patients who met the inclusion criteria were retrospectively reviewed. 14 (82.4%) had previously undergone surgery, 15 (88.2%) had received conventional EBRT and 3 (17.6%) had chosen chemotherapy. The number of 125I seeds implanted ranged from 7 to 122 (median 79) with specific activity of 0.5-0.8 mCi (median 0.7 mCi). The post-plan showed that the actuarial D90 of 125I seeds were 90–183 Gy (median 137 Gy). The follow-up period ranged from 2 to 69 months (median 19 months). The local control rate was calculated by the Kaplan-Meier method. For 5 Chondrosarcomas, the 1-, 2-, 3-year local control rates were 75%, 37.5%, and 37.5%, respectively, with a median of 34 months (range, 4–39 months). For 4 chordomas, the local control rate was 50% with a median follow-up of 13 months (range, 3–17 months). For 3 fibromatosis, all of them were survival without local recurrence at the end of follow-up. During the follow-up period, 35.3% (6/17) died from metastases, 17.6% (3/17) developed local recurrence by 8, 14 and 34 months while 64.7% (11/17) remained alive. 100% experienced pain relief and normal or improved ambulation, without more than Frankel grade 3 radiation myelopathy. Percutaneous 125I seed implantation can be an alternative or retreatment for recurrent spinal primary tumors.
- 23 December 2014
- Published by Springer Nature in Radiation Oncology
- Vol. 9 (1) , 301
Open AccessCT-guidance interstitial 125Iodine seed brachytherapy as a salvage therapy for recurrent spinal primary tumors
Management of spinal neoplasms has relied on open surgery and external beam radiotherapy (EBRT). Although primary spinal tumors are rare, their treatment remains a pervasive problem. This analysis sought to evaluate the safety and efficacy of CT-guided 125I seed brachytherapy for recurrent paraspinous and vertebral primary tumors. From November 2002 to June 2014, 17 patients who met the inclusion criteria were retrospectively reviewed. 14 (82.4%) had previously undergone surgery, 15 (88.2%) had received conventional EBRT and 3 (17.6%) had chosen chemotherapy. The number of 125I seeds implanted ranged from 7 to 122 (median 79) with specific activity of 0.5-0.8 mCi (median 0.7 mCi). The post-plan showed that the actuarial D90 of 125I seeds were 90–183 Gy (median 137 Gy). The follow-up period ranged from 2 to 69 months (median 19 months). The local control rate was calculated by the Kaplan-Meier method. For 5 Chondrosarcomas, the 1-, 2-, 3-year local control rates were 75%, 37.5%, and 37.5%, respectively, with a median of 34 months (range, 4–39 months). For 4 chordomas, the local control rate was 50% with a median follow-up of 13 months (range, 3–17 months). For 3 fibromatosis, all of them were survival without local recurrence at the end of follow-up. During the follow-up period, 35.3% (6/17) died from metastases, 17.6% (3/17) developed local recurrence by 8, 14 and 34 months while 64.7% (11/17) remained alive. 100% experienced pain relief and normal or improved ambulation, without more than Frankel grade 3 radiation myelopathy. Percutaneous 125I seed implantation can be an alternative or retreatment for recurrent spinal primary tumors.
- Open Access
- 27 December 2013
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 32 (1) , 106
The investigation of 125I seed implantation as a salvage modality for unresectable pancreatic carcinoma
To assess the efficacy of intraoperative ultrasound-guided implantation of 125I seeds for the treatment of unresectable pancreatic carcinoma, and analyze the associated prognostic factors.
- 27 December 2013
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 32 (1) , 106
Open AccessThe investigation of 125I seed implantation as a salvage modality for unresectable pancreatic carcinoma
To assess the efficacy of intraoperative ultrasound-guided implantation of 125I seeds for the treatment of unresectable pancreatic carcinoma, and analyze the associated prognostic factors.